221 related articles for article (PubMed ID: 29471921)
1. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
[TBL] [Abstract][Full Text] [Related]
2. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
3. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
[TBL] [Abstract][Full Text] [Related]
4. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Makarenko I; Mazhnaya A; Marcus R; Bojko MJ; Madden L; Filippovich S; Dvoriak S; Altice FL
Int J Drug Policy; 2017 Jul; 45():56-63. PubMed ID: 28628853
[TBL] [Abstract][Full Text] [Related]
6. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
7. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
Morozova O; Dvoriak S; Pykalo I; Altice FL
Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
[TBL] [Abstract][Full Text] [Related]
8. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
9. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
[TBL] [Abstract][Full Text] [Related]
11. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
12. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
13. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
Madden L; Bojko MJ; Farnum S; Mazhnaya A; Fomenko T; Marcus R; Barry D; Ivanchuk I; Kolomiets V; Filippovych S; Dvoryak S; Altice FL
Int J Drug Policy; 2017 Nov; 49():48-53. PubMed ID: 28957756
[TBL] [Abstract][Full Text] [Related]
14. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
Bruce RD; Dvoryak S; Sylla L; Altice FL
Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
[TBL] [Abstract][Full Text] [Related]
16. Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment.
Hallinan R; Elsayed M; Espinoza D; Veillard AS; Morley KC; Lintzeris N; Haber P
Subst Use Misuse; 2019; 54(10):1589-1598. PubMed ID: 31131668
[No Abstract] [Full Text] [Related]
17. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.
Lo A; Kerr T; Hayashi K; Milloy MJ; Nosova E; Liu Y; Fairbairn N
J Subst Abuse Treat; 2018 Nov; 94():41-46. PubMed ID: 30243416
[TBL] [Abstract][Full Text] [Related]
18. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.
Bojko MJ; Mazhnaya A; Marcus R; Makarenko I; Islam Z; Filippovych S; Dvoriak S; Altice FL
J Subst Abuse Treat; 2016 Jul; 66():37-47. PubMed ID: 27211995
[TBL] [Abstract][Full Text] [Related]
19. Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.
Dumchev K; Dvoryak S; Chernova O; Morozova O; Altice FL
Int J Drug Policy; 2017 Oct; 48():44-53. PubMed ID: 28800420
[TBL] [Abstract][Full Text] [Related]
20. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine.
Mazhnaya A; Marcus R; Bojko MJ; Zelenev A; Makarenko I; Pykalo I; Filippovych S; Dvoriak S; Altice FL
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):288-295. PubMed ID: 30312275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
